Healthcare

Amgen inserts $66m into Oxford Nanopore
Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.
Berkeley Lights attracts Nikon for $95m round
The cell biology technology developer, based on UC Berkeley research, took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.
Palette adds colour with Nestlé partnership
Karolinska Institute spinout Palette Life Sciences will add three medical products based on Nestlé’s intellectual property to its existing program targeting pain suffered during gynaecological procedures.
Locate Bio pinpoints $660,000 round
Mercia Technologies has returned to back Locate Bio's pursuit of orthopaedic therapies based on research at University of Nottingham.
UBEF II carries funding to Vitamica
University of Bristol Enterprise Fund II has backed antibiotic diagnostics developer Vitamica, which spun out of the university’s school of physics in January 2018.
Kentucky to lead commercialisation hub
University of Kentucky will lead a consortium of academic institutions participating in a US government-funded commercialisation hub intended to accelerate biomedical research.
Indiana duo meet BioCrossroads for $9m fund
University of Notre Dame and Indiana University have both backed a $9m seed fund aimed at supporting local businesses in life sciences, health IT and agricultural biosciences.
Edison Partners welcomes Rutgers to $365m fund
Rutgers University was among a string of limited partners for the growth equity firm's ninth fund, which was oversubscribed from its $300m target.

Other News

Breethe inhales $3.5m
University of Maryland-founded artificial lung developer Breethe is targeting $5m for its latest round after previously raising approximately $7.8m.
Cardialen jumpstarts $17m series B
The George Washington spinout had previously raised $4.1m in equity for its low-voltage implantable cardiac defibrillator.
Canada puts $25m into Toronto’s Creative Destruction
Canada’s Strategic Innovation Fund will provide $19.2m for accelerator Creative Destruction Lab over four years with the aim of supporting more than 1,300 science-focused companies.
Rgenix generates $40m series C
The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.
Gotham goes to $54m in series A
Cornell spinout Gotham Therapeutics has come out of stealth with a series A round co-led by SR One, Versant Ventures and Forbion.
Glympse Bio engineers $22m series A
Glympse Bio, a medical diagnostic sensor spinout from MIT, has secured $22m in a series A round ahead of clinical trials targeting fatty liver disease and cancer.

Editor's Picks

Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Ambys arrives at $140m investment
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Big deal: Roche derives MS treatment
Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
test reg

Login

Not yet subscribed?

See your subscription offers here